🚀 VC round data is live in beta, check it out!
Abclon Valuation Multiples
Discover revenue and EBITDA valuation multiples for Abclon and similar public comparables like Zentiva, Astria Therapeutics, MiMedx Group, Guizhou Sanli and more.
Abclon Overview
About Abclon
Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO.
Founded
2010
HQ
Employees
63
Website
Financials (FY)
EV
$714M
Abclon Financials
Abclon reported last fiscal year revenue of $3M and negative EBITDA of ($11M).
In the same fiscal year, Abclon generated $758K in gross profit, ($11M) in EBITDA losses, and had net loss of ($12M).
Abclon P&L
In the most recent fiscal year, Abclon reported revenue of $3M and EBITDA of ($11M).
Abclon expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $758K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 24% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($11M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (347%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (374%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (380%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Abclon Stock Performance
Abclon has current market cap of $717M, and enterprise value of $714M.
Market Cap Evolution
Abclon's stock price is $37.56.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $714M | $717M | 0.0% | XXX | XXX | XXX | $-0.62 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbclon Valuation Multiples
Abclon trades at 228.0x EV/Revenue multiple, and (65.8x) EV/EBITDA.
Abclon Financial Valuation Multiples
As of March 23, 2026, Abclon has market cap of $717M and EV of $714M.
Equity research analysts estimate Abclon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abclon has a P/E ratio of (60.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $717M | XXX | $717M | XXX | XXX | XXX |
| EV (current) | $714M | XXX | $714M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 228.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (65.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (60.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 942.6x | XXX | XXX | XXX |
| P/E | — | XXX | (60.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (74.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abclon Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Abclon Margins & Growth Rates
Abclon's revenue in the last fiscal year grew by 102%.
Abclon Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 102% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (347%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 18% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 306% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 398% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Abclon Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| Astria Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| MiMedx Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Guizhou Sanli | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmicell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abclon M&A Activity
Abclon acquired XXX companies to date.
Last acquisition by Abclon was on XXXXXXXX, XXXXX. Abclon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Abclon
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAbclon Investment Activity
Abclon invested in XXX companies to date.
Abclon made its latest investment on XXXXXXXX, XXXXX. Abclon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Abclon
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abclon
| When was Abclon founded? | Abclon was founded in 2010. |
| Where is Abclon headquartered? | Abclon is headquartered in South Korea. |
| How many employees does Abclon have? | As of today, Abclon has over 63 employees. |
| Who is the CEO of Abclon? | Abclon's CEO is Jong-Seo Lee. |
| Is Abclon publicly listed? | Yes, Abclon is a public company listed on Korea Exchange. |
| What is the stock symbol of Abclon? | Abclon trades under 174900 ticker. |
| When did Abclon go public? | Abclon went public in 2017. |
| Who are competitors of Abclon? | Abclon main competitors are Zentiva, Astria Therapeutics, MiMedx Group, Guizhou Sanli. |
| What is the current market cap of Abclon? | Abclon's current market cap is $717M. |
| What is the current revenue of Abclon? | Abclon's last fiscal year revenue is $3M. |
| What is the current EV/Revenue multiple of Abclon? | Current revenue multiple of Abclon is 228.0x. |
| Is Abclon profitable? | No, Abclon is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.